Tag Archives: scmp

Sucampo Stock Hits High On EPS, But CVS Nixes Drug

Specialty drugmaker Sucampo Pharmaceuticals (SCMP) beat Q2 expectations and raised its guidance early Wednesday, sending the stock to a new high in early trading. It pulled back later, however, possibly because word got out that its sole marketed drug is being excluded from CVS’ (CVS) preferred formulary next year. Sucampo reported earnings of 21 cents a share, up from just 4 cents in the year-earlier quarter and 6 cents above analysts’ consensus,

Sucampo Stock Rebounds As Drug Gets Fast-Track Review

Specialty drugmaker Sucampo Pharmaceuticals (SCMP) was up more than 6% Friday following a volatile week of trading, after the company’s lead drug was granted accelerated review by the FDA. Late Thursday, Sucampo said the FDA had granted its drug candidate cobiprostone fast-track designation as a treatment for oral mucositis, or inflammation of the mucus membranes in the mouth. The company still has a ways to go to get it on the market, though, as

Sucampo Stock Spikes On Bullish Initiation Report

Hot biotech Sucampo Pharmaceuticals (SCMP) rose more than 10% in early trading Monday after Guggenheim launched coverage with a buy rating, seeing multiple growth drivers ahead. Analyst Louise Chen wrote that Sucampo’s constipation drug Amitiza still has growth potential, despite growing competition from Actavis’ (ACT) and Ironwood ‘s (IRWD) Linzess. She added that further indications and formulations of Amitiza that are in development, along with